The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer
Open accessAbstract
Purpose: In the absence of high-level evidence or clinical guidelines supporting any given active treatment approach over another for localized prostate cancer, clinician and patient preferences may lead to substantial variation in treatment use. Methods: Data were analyzed from 36 clinical sites that contributed data to the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry. Distribution of primary treatment use was measured over time. Prostate cancer risk was assessed using the D'Amico risk groups and the Cancer of the Prostate Risk Assessment (CAPRA) score. Descriptive analyses were performed, and a hierarchical model was constructed that controlled for year of diagnosis, cancer risk variables, and other patient factors to estimate the proportion of variation in primary treatment selection explicable by practice site. Results: Among 11,892 men analyzed, 6.8% elected surveillance, 49.9% prostatectomy, 11.6% external-beam radiation, 13.3% brachytherapy, 4.0% cryoablation, and 14.4% androgen deprivation monotherapy. Prostate cancer risk drives treatment selection, but the data suggest both overtreatment of low-risk disease and undertreatment of high-risk disease. The former trend appears to be improving over time, while the latter is worsening. Treatment varies with age, comorbidity, and socioeconomic status. However, treatment patterns vary markedly across clinical sites, and this variation is not explained by case-mix variability or known patient factors. Practice site explains a proportion of this variation ranging from 13% for androgen deprivation monotherapy to 74% for cryoablation. Conclusion: Substantial variation exists in management of localized prostate cancer that is not explained by measurable factors. A critical need exists for high-quality comparative effectiveness research in localized prostate cancer to help guide treatment decision making.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
Thompson, I., Thrasher, J. B., Aus, G., Burnett, A. L., Canby-Hagino, E. D., Cookson, M. S., D’Amico, A. V., Dmochowski, R. R., Eton, D. T., Forman, J. D., et al. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.03.003 · Cited by 1,113
Bill-Axelson, A., Holmberg, L., Filen, F., Ruutu, M., Garmo, H., Busch, C., Nordling, S., Haggman, M., Andersson, S.-O., Bratell, S., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn255 · Cited by 603
Wilt, T. J., MacDonald, R., Rutks, I., Shamliyan, T. A., Taylor, B. C., & Kane, R. L. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-6-200803180-00209 · Cited by 597
Wei, J. T., Dunn, R. L., Sandler, H. M., McLaughlin, P. W., Montie, J. E., Litwin, M. S., NYQUIST, L. V., & Sanda, M. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.557 · Cited by 443
Outcomes of Localized Prostate Cancer Following Conservative Management
Lu-Yao, G. L. (2009) · JAMA · doi:10.1001/jama.2009.1348 · Cited by 430
O'Connor, A. M., Llewellyn-Thomas, H. A., & Flood, A. B. (2004) · Health Affairs · doi:10.1377/hlthaff.var.63 · Cited by 363
COOPERBERG, M. R., BROERING, J. M., LITWIN, M. S., LUBECK, D. P., MEHTA, S. S., HENNING, J. M., CARROLL, P. R., & the CaPSURE INVESTIGATORS (2004) · Journal of Urology · doi:10.1097/01.ju.0000107247.81471.06 · Cited by 340
Self-citationRisk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis
Cooperberg, M. R., Broering, J. M., & Carroll, P. R. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp122 · Cited by 336
Self-citationNational Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer
Cooperberg, M. R., Grossfeld, G. D., Lubeck, D. P., & Carroll, P. R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.981 · Cited by 329
Self-citationThe capsure database: a methodology for clinical practice and research in prostate cancer
Lubeck, D. P., Litwin, M. S., Henning, J. M., Stier, D. M., Mazonson, P., Fisk, R., Carroll, P. R., & panel, T. C. R. (1996) · Urology · doi:10.1016/s0090-4295(96)00226-9 · Cited by 268
Self-citationBaicker, K., Chandra, A., Skinner, J. S., & Wennberg, J. E. (2004) · Health Affairs · doi:10.1377/hlthaff.var.33 · Cited by 268
Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate Cancer in the United States
Miller, D. C., Gruber, S. B., Hollenbeck, B. K., Montie, J. E., & Wei, J. T. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj308 · Cited by 227
High-risk prostate cancer in the United States, 1990–2007
Cooperberg, M. R., Cowan, J., Broering, J. M., & Carroll, P. R. (2008) · World Journal of Urology · doi:10.1007/s00345-008-0250-7 · Cited by 200
Self-citationWilt, T. J., Brawer, M. K., Barry, M. J., Jones, K. M., Kwon, Y., Gingrich, J. R., Aronson, W. J., Nsouli, I., Iyer, P., Cartagena, R., et al. (2009) · Contemporary Clinical Trials · doi:10.1016/j.cct.2008.08.002 · Cited by 170
Donovan, J., Lane, J. A., Peters, T. J., Brindle, L. A., Salter, E., Gillatt, D. A., Powell, P. H., Bollina, P. R., Neal, D. E., & Hamdy, F. C. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.02.010 · Cited by 159
Determinants of Androgen Deprivation Therapy Use for Prostate Cancer: Role of the Urologist
Shahinian, V. B., Kuo, Y., Freeman, J. L., & Goodwin, J. S. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj230 · Cited by 129
Davison, B. J., So, A., & Goldenberg, S. L. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07043.x · Cited by 126
Treatment decision‐making strategies and influences in patients with localized prostate carcinoma
Gwede, C. K., Pow‐Sang, J. M., Seigne, J. D., Heysek, R. V., Helal, M. A., Shade, K., Cantor, A. B., & Jacobsen, P. B. (2005) · Cancer · doi:10.1002/cncr.21330 · Cited by 118
Wallace, K., Fleshner, N. E., Jewett, M. A. S., Basiuk, J., & Crook, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3875 · Cited by 86
Patient Preferences in Prostate Cancer: A Clinician's Guide to Understanding Health Utilities
Kramer, K. M., Bennett, C. L., Pickard, A. S., Lyons, E. A., Wolf, M. S., McKoy, J. M., & Knight, S. J. (2005) · Clinical Prostate Cancer · doi:10.3816/cgc.2005.n.007 · Cited by 26
Cited by
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Klein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1437 · Cited by 1,787
Radical Prostatectomy versus Observation for Localized Prostate Cancer
Wilt, T. J., Brawer, M. K., Jones, K. M., Barry, M. J., Aronson, W. J., Fox, S., Gingrich, J. R., Wei, J. T., Gilhooly, P., Grob, B. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113162 · Cited by 1,770
Bulten, W., Pinckaers, H., van Boven, H., Vink, R., de Bel, T., van Ginneken, B., van der Laak, J., Hulsbergen-van de Kaa, C., & Litjens, G. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30739-9 · Cited by 705
Klein, E. A., Cooperberg, M. R., Magi-Galluzzi, C., Simko, J. P., Falzarano, S. M., Maddala, T., Chan, J. M., Li, J., Cowan, J. E., Tsiatis, A. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.004 · Cited by 659
Self-citation
Metadata
- Authors
- Cooperberg, M. R., Broering, J. M., & Carroll, P. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-03-01
- Volume
- 28
- Issue
- 7
- Pages
- 1117-1123
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160217483
- Cited by
- 1,006
- References
- 21
- FWCI
- 68.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.